诊断学理论与实践

诊断学理论与实践 ›› 2018, Vol. 17 ›› Issue (02): 191-196.doi: 10.16150/j.1671-2870.2018.02.014

• 论著 • 上一篇    下一篇

双源双能量CT碘值在评估进展期胃腺癌新辅助化疗疗效中的价值

张阳1, 张欢1, 闫静2, 杲霄源3, 谭晶文1, 武新洋1, 严福华1   

  1. 1.上海交通大学医学院附属瑞金医院放射科,上海 200025;
    2.西门子（中国）有限公司,上海 201318;
    3.滨州医学院附属医院放射科,山东 滨州 256603
  • 收稿日期:2017-10-04 出版日期:2018-04-25 发布日期:2018-04-25
  • 通讯作者: 张欢 E-mail: huanzhangy@126.com
  • 基金资助:
    国家自然科学基金（U1532107,81771789）

Iodine value in dual source dual energy CT for evaluating the efficacy of neoadjuvant chemotherapy on advanced gastric adenocarcinoma

ZHANG Yang1, ZHANG Huan1, YAN Jing2, GAO Xiaoyuan3, TAN Jingwen1, WU Xinyang1, YAN Fuhua1   

  1. 1. Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China;
    2. Siemens Ltd China, Shanghai 201318, China;
    3. Department of Radiology, Affiliated Hospital of Binzhou Medical University, Shandong Binzhou 256603, China
  • Received:2017-10-04 Online:2018-04-25 Published:2018-04-25

PDF (PC)

54

摘要： 目的：探讨双源双能量CT（以下简称双能量CT）扫描结果中病灶标准化碘值与非标准化碘值间是否有差异,并评估碘值在进展期胃腺癌化疗疗效评价中的应用价值。方法：对48例经胃镜病理检查证实为腺癌的患者行新辅助化疗,分析化疗前后双能量CT扫描图像,计算病灶化疗前、后门脉期及延迟期的标准化碘值变化率及非标准化碘值变化率;并以实体瘤疗效评价标准（Response Evaluation Criteria in Solid Tumors, RECIST）1.1分为反应组与非反应组,比较2组间化疗前、后各碘值及其变化率的差异。结果：①门脉期所有患者胃原发灶的各非标准碘值变化率与标准化碘值变化率相比,差异均无统计学意义（P>0.05）,延迟期也具有相同的表现（P>0.05）。②反应组化疗后病灶各碘值在门脉期均明显小于非反应组[数值用（均数±标准差）或中位数（四分位差）表示][化疗后门脉期碘摄取浓度,（1.71±0.49） mg/mL 比（2.15±0.55） mg/mL,P=0.008;化疗后标准化门脉期碘摄取浓度,0.30±0.09比0.38±0.10,P=0.003;化疗后门脉期总碘摄取量,18.30 mg（27.15 mg）比81.55 mg（81.20 mg）,P<0.001;化疗后标准化门脉期总碘摄取量,15.86（22.65）比47.97（64.05）,P<0.001]。③反应组病灶的总碘摄取量减少率在门脉期及延迟期均明显大于非反应组[化疗前后门脉期总碘摄取量减少率,-83.34%（21.05%）比-39.82%（47.90%）,P<0.001; 化疗前后门脉期标准化总碘摄取量减少率,-80.28%（19.61%）比-42.33%（41.12%）,P<0.001;化疗前后延迟期总碘摄取量减少率,-80.66%（19.97%）比-36.99%（37.71%）,P<0.001;化疗前后延迟期标准化总碘摄取量减少率,-79.57%（24.89%）比-37.79%（36.48%）,P<0.001]。结论：病灶化疗前、后的标准化碘值变化率与非标准化碘值变化率间差异无统计学意义,利用双能量CT扫描测得的病灶化疗后碘值及各碘值变化率（尤其是病灶的总碘摄取量减少率）在评估进展期胃腺癌新辅助化疗疗效中有一定价值。

关键词: 胃腺癌, 双源双能量CT, 碘值, 新辅助化疗

Abstract: Objective: To assess the iodine value in dual source dual energy CT (DSDECT) for evaluating the efficacy of neoadjuvant chemotherapy on advanced gastric adenocarcinoma and comparing the standardized iodine value and non-standardized iodine value in lesions as well as the difference in reduction ratio of iodine value before and after neoadjuvant chemotherapy. Methods: A total of 48 patients with pathologically confirmed gastric adenocarcinoma via endoscopy were enrolled and neoadjuvant chemotherapy was conducted. The DSDECT images before and after chemotherapy were analyzed to compare the difference between the reduction ratio of standardized iodine values (which were normalized with abdominal aorta) and non-standardized iodine values in portal phase and delayed phase. According to RECIST1.1 criteria, patients were divided into response group and non-response group. The differences in iodine value as well as reduction ratio of iodine value of lesions before and after neoadjuvant chemotherapy were compared between response and non-response groups. Results: ① There were no significant differences in the reduction ratio of standardized iodine values and non-standardized iodine values before and after neoadjuvant chemotherapy in both portal phase and delayed phase(P>0.05). ② The iodine values after neoadjuvant chemotherapy in the response group were significantly lower than those of the non-response group in the portal phase [values are expressed as (mean ± standard deviation) or median (guartile deviation)][iodine uptake in portal phase(IU-P), （1.71±0.49） mg/mL vs （2.15±0.55）mg/mL, P=0.008; normalized iodine uptake in portal phase(NIU-P), （0.30±0.09） vs （0.38±0.10）, P=0.003; total iodine uptake in portal phase (TIU-P): 18.30 mg（27.15 mg） vs 81.55 mg（81.20 mg）, P<0.001; normalized total iodine uptake in portal phase (NTIU-P): 15.86（22.65） vs 47.97（64.05）, P<0.001]. ③ The reduction ratio of total iodine uptake before and after neoadjuvant chemotherapy in response group were significantly higher than those in non-response group in both portal and delayed phase [ΔTIU-P, -83.34%（21.05%） vs -39.82%（47.90%）, P<0.001; ΔNTIU-P, -80.28%（19.61%） vs -42.33%（41.12%）, P<0.001; ΔTIU-D, -80.66%（19.97%） vs -36.99%（37.71%）, P<0.001; ΔNTIU-D, -79.57%（24.89%） vs -37.79%（36.48%）, P<0.001]. Conclusions: The iodine values and the reduction ratio of the iodine values after neoadjuvant chemotherapy obtained from DSDECT can be helpful for evaluating the efficacy of neoadjuvant chemotherapy on advanced gastric adenocarcinoma.

Key words: Gastric adenocarcinoma, Dual-source dual-energy CT, Iodine value, Neoadjuvant chemotherapy

中图分类号: